UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 27, 2014

Commission File Number: 000-53290

CHROMADEX CORPORATION
(Exact Name of Registrant as Specified in its Charter)
 
Delaware   26-2940963
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
10005 Muirlands Blvd. Suite G, Irvine, California   92618
(Address of Principal Executive Offices)   (Zip Code)
 
Registrant's telephone number, including area code: (949) 419-0288
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X]   No [   ]
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X]   No [   ]
 
Indicate by check mark whether the registrant is a large accelerated filer, accelerated filer, non-accelerated filer or smaller reporting company. See definition of “large accelerated filer, accelerated filer and smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer [   ] Accelerated filer [   ]
Non-accelerated filer [   ] Smaller reporting company [X]
(Do not check if smaller reporting company)  
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [   ]   No [X]
 
Number of shares of common stock of the registrant: 106,924,193 outstanding as of November 5, 2014.
 


 

 
 
CHROMADEX CORPORATION
 
2014 QUARTERLY REPORT ON FORM 10-Q
 
TABLE OF CONTENTS
 
    Page
PART I  –
FINANCIAL INFORMATION (UNAUDITED)
 
  1
  Condensed Consolidated Balance Sheets as of September 27, 2014 and December 28, 2013 (Unaudited) 1
  Condensed Consolidated Statements of Operations for the three months ended September 27, 2014 and September 28, 2013 (Unaudited) 2
  Condensed Consolidated Statements of Operations for the nine months ended September 27, 2014 and September 28, 2013 (Unaudited) 3
  Condensed Consolidated Statements of Stockholders Equity for the nine months ended September 27, 2014 (Unaudited) 4
  Condensed Consolidated Statements of Cash Flows for the nine months ended September 27, 2014 and September 28, 2013 (Unaudited) 5
  Notes to Condensed Consolidated Financial Statements (Unaudited) 6
  19
  25
  25
     
PART II  –
OTHER INFORMATION
 
  26
  26
  26
  26
  26
  26
   

 
PART I – FINANCIAL INFORMATION (UNAUDITED)
 
ITEM 1.     FINANCIAL STATEMENTS
 
ChromaDex Corporation and Subsidiaries
   
     
Condensed Consolidated Balance Sheets (Unaudited)
   
September 27, 2014 and December 28, 2013
   
 
   
September 27, 2014
   
December 28, 2013
 
Assets
           
             
Current Assets
           
    Cash
  $ 1,203,758     $ 2,261,336  
    Trade receivables, less allowance for doubtful accounts and returns  September 27, 2014 $33,000; December 28, 2013 $9,000
    2,528,638       838,793  
    Other receivable
    -       215,000  
    Inventories
    2,286,086       2,204,125  
    Prepaid expenses and other assets
    294,296       271,445  
          Total current assets
    6,312,778       5,790,699  
                 
Leasehold Improvements and Equipment, net
    1,293,702       1,063,239  
                 
Other Noncurrent Assets
               
    Deposits
    52,046       43,460  
    Long-term investment in affiliate
    773,801       1,887,844  
    Intangible assets, net
    266,824       201,650  
          Total other noncurrent assets
    1,092,671       2,132,954  
                 
          Total assets
  $ 8,699,151     $ 8,986,892  
                 
Liabilities and Stockholders' Equity
               
                 
Current Liabilities
               
    Accounts payable
  $ 2,270,645     $ 1,440,910  
    Accrued expenses
    857,854       656,707  
    Current maturities of capital lease obligations
    162,566       138,887  
    Customer deposits and other
    225,917       546,044  
    Deferred rent, current
    65,040       55,586  
          Total current liabilities
    3,582,022       2,838,134  
                 
Capital lease obligations, less current maturities
    456,969       280,342  
                 
Deferred rent, less current
    156,779       202,965  
                 
          Total liabilities
    4,195,770       3,321,441  
                 
Commitments and contingencies
               
                 
Stockholders' Equity
               
    Common stock, $.001 par value; authorized 150,000,000 shares; issued and outstanding September 27, 2014 105,239,985 and  December 28, 2013 104,524,738 shares
    105,240       104,525  
    Additional paid-in capital
    42,695,089       39,697,063  
    Accumulated deficit
    (38,296,948 )     (34,136,137 )
          Total stockholders' equity
    4,503,381       5,665,451  
                 
          Total liabilities and stockholders' equity
  $ 8,699,151     $ 8,986,892  
                 
See Notes to Condensed Consolidated Financial Statements.
 
ChromaDex Corporation and Subsidiaries
   
     
Condensed Consolidated Statements of Operations (Unaudited)
 
For the Three Month Periods Ended September 27, 2014 and September 28, 2013
 
   
September 27, 2014
   
September 28, 2013
 
             
Sales, net
  $ 4,139,710     $ 2,718,207  
Cost of sales
    2,616,764       1,968,020  
                 
Gross profit
    1,522,946       750,187  
                 
Operating expenses:
               
Sales and marketing
    518,662       505,068  
General and administrative
    1,651,718       1,453,611  
Loss from investment in affiliate
    -       33,281  
Operating expenses
    2,170,380       1,991,960  
                 
Operating loss
    (647,434 )     (1,241,773 )
                 
Nonoperating income (expense):
               
Interest income
    230       179  
Interest expense
    (12,449 )     (8,669 )
Nonoperating expenses
    (12,219 )     (8,490 )
                 
Net loss
  $ (659,653 )   $ (1,250,263 )
                 
Basic and Diluted loss per common share
  $ (0.01 )   $ (0.01 )
                 
Basic and Diluted weighted average common shares outstanding
    106,610,400       101,309,939  
                 
See Notes to Condensed Consolidated Financial Statements.

 
ChromaDex Corporation and Subsidiaries
   
     
Condensed Consolidated Statements of Operations (Unaudited)
   
For the Nine Month Periods Ended September 27, 2014 and September 28, 2013
 
 
   
September 27, 2014
   
September 28, 2013
 
             
Sales, net
  $ 11,070,002     $ 7,759,668  
Cost of sales
    7,163,282       5,375,903  
                 
Gross profit
    3,906,720       2,383,765  
                 
Operating expenses:
               
Sales and marketing
    1,554,777       1,866,051  
General and administrative
    6,458,027       4,155,792  
Loss from investment in affiliate
    21,543       33,281  
Operating expenses
    8,034,347       6,055,124  
                 
Operating loss
    (4,127,627 )     (3,671,359 )
                 
Nonoperating income (expense):
               
Interest income
    1,175       679  
Interest expense
    (34,359 )     (24,521 )
Nonoperating expenses
    (33,184 )     (23,842 )
                 
Net loss
  $ (4,160,811 )   $ (3,695,201 )
                 
Basic and Diluted loss per common share
  $ (0.04 )   $ (0.04 )
                 
Basic and Diluted weighted average common shares outstanding
    106,290,782       98,590,008  
                 
See Notes to Condensed Consolidated Financial Statements.


ChromaDex Corporation and Subsidiaries
         
Condensed Consolidated Statement of Stockholders' Equity (Unaudited)
   
For the Nine Month Period Ended September 27, 2014
       
 
   
Common Stock
   
Additional
Paid-in
   
Accumulated
   
Total
Stockholders'
 
   
Shares
   
Amount
   
Capital
   
Deficit
   
Equity
 
Balance, December 28, 2013
    104,524,738     $ 104,525     $ 39,697,063     $ (34,136,137 )   $ 5,665,451  
                                         
Exercise of stock options
    34,363       34       27,066       -       27,100  
                                         
Issuance of unvested restricted stock
    1,090,000       1,090       -       -       1,090  
                                         
Unvested restricted stock
    (1,090,000 )     (1,090 )     -       -       (1,090 )
                                         
Share-based compensation
    -       -       949,943       -       949,943  
                                         
Net loss
    -       -       -       (1,848,016 )     (1,848,016 )
                                         
Balance, March 29, 2014
    104,559,101     $ 104,559     $ 40,674,072     $ (35,984,153 )   $ 4,794,478  
                                         
Exercise of stock options
    24,136       24       17,971       -       17,995  
                                         
Issuance of unvested restricted stock
    96,000       96       -       -       96  
                                         
Unvested restricted stock
    (96,000 )     (96 )     -       -       (96 )
                                         
Share-based compensation
    6,000       6       1,030,689       -       1,030,695  
                                         
Stock issued to settle outstanding payable balance
    126,605       127       128,367       -       128,494  
                                         
Net loss
    -       -       -       (1,653,142 )     (1,653,142 )
                                         
Balance, June 28, 2014
    104,715,842     $ 104,716     $ 41,851,099     $ (37,637,295 )   $ 4,318,520  
                                         
Exercise of stock options
    453,143       453       403,610       -       404,063  
                                         
Share-based compensation
    71,000       71       431,380       -       431,451  
                                         
Stock issued to settle outstanding payable balance
    -       -       9,000       -       9,000  
                                         
Net loss
    -       -       -       (659,653 )     (659,653 )
                                         
Balance, September 27, 2014
    105,239,985     $ 105,240     $ 42,695,089     $ (38,296,948 )   $ 4,503,381  
                                         
See Notes to Condensed Consolidated Financial Statements.
ChromaDex Corporation and Subsidiaries
   
     
Condensed Consolidated Statements of Cash Flows (Unaudited)
   
For the Nine Month Periods Ended September 27, 2014 and September 28, 2013
 
   
September 27, 2014
   
September 28, 2013
 
Cash Flows From Operating Activities
           
  Net loss
  $ (4,160,811 )   $ (3,695,201 )
  Adjustments to reconcile net loss to net cash  used in operating activities:
               
    Depreciation of leasehold improvements and equipment
    161,712       187,667  
    Amortization of intangibles
    24,826       16,819  
    Share-based compensation expense
    2,467,720       1,059,653  
    Gain on exchange of equipment
    (17,301 )     -  
    Loss from disposal of equipment
    -       68,378  
    Loss from investment in affiliate
    21,543       33,281  
  Changes in operating assets and liabilities:
               
    Trade receivables
    (1,689,845 )     931,904  
    Other receivable
    215,000       -  
    Inventories
    (81,961 )     (479,924 )
    Prepaid expenses and other assets
    (87,068 )     (50,991 )
    Accounts payable
    967,229       (712,138 )
    Accrued expenses
    201,147       72,336  
    Customer deposits and other
    (320,127 )     349,378  
    Deferred rent
    (36,732 )     45,661  
Net cash used in operating activities
    (2,334,668 )     (2,173,177 )
                 
Cash Flows From Investing Activities
               
  Purchases of leasehold improvements and equipment
    (53,428 )     (117,523 )
  Purchases of intangible assets
    (90,000 )     (69,000 )
  Proceeds from sale of assets
    -       1,000,000  
  Proceeds from sale of equipment
    1,356       -  
  Proceeds from investment in affiliate
    1,092,500       225,000  
Net cash provided by investing activities
    950,428       1,038,477  
                 
Cash Flows From Financing Activities
               
  Proceeds from exercise of stock options
    449,158       138,369  
  Proceeds from exercise of warrants
    -       1,638,748  
  Principal payments on capital leases
    (122,496 )     (74,993 )
Net cash provided by financing activities
    326,662       1,702,124  
                 
Net (decrease) increase in cash
    (1,057,578 )     567,424  
                 
Cash Beginning of Period
    2,261,336       520,000  
                 
Cash Ending of Period
  $ 1,203,758     $ 1,087,424  
                 
Supplemental Disclosures of Cash Flow Information
               
  Cash payments for interest
  $ 34,359     $ 24,521  
                 
Supplemental Schedule of Noncash Investing Activity
               
  Capital lease obligation incurred for purchases of equipment
  $ 322,802     $ 171,851  
  Retirement of fully depreciated equipment - cost
  $ 56,110     $ -  
  Retirement of fully depreciated equipment - accumulated depreciation
  $ (56,110 )   $ -  
                 
Supplemental Schedule of Noncash Operating Activity
               
  Stock issued to settle outsanding payable balance
  $ 137,494     $ -  
                 
Supplemental Schedule of Noncash Share-based Compensation
               
  Stock awards issued for services rendered in prior period
  $ -     $ 14,560  
  Changes in prepaid expenses associated with share-based compensation
  $ 55,631     $ 119,375  
                 
Supplemental Schedule of Noncash Activities Related to
               
  Sale of BluScience Consumer Product Line
               
     Assets transferred
  $ -     $ 3,526,677  
     Liabilities transferred
  $ -     $ 368,873  
     Carrying value of long-term investment in affiliate,  net of $1,000,000 cash proceeds
  $ -     $ 2,157,804  
                 
See Notes to Condensed Consolidated Financial Statements.
               
 
Note 1.   Interim Financial Statements
 
The accompanying financial statements of ChromaDex Corporation (the “Company”) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of September 27, 2014 and results of operations and cash flows for the three and nine months ended September 27, 2014 and September 28, 2013. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 28, 2013 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 27, 2014. Operating results for the nine months ended September 27, 2014 are not necessarily indicative of the results to be achieved for the full year ending on January 3, 2015.  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
 
The balance sheet at December 28, 2013 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
 
Note 2.   Nature of Business and Liquidity
 
Nature of business :  The Company is a natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its business model that utilizes its wholly owned business units, including ingredient technologies, natural product fine chemicals (known as “phytochemicals”), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting).  The Company provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.  The Company acquired Spherix Consulting, Inc. on December 3, 2012, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
 
Liquidity :  The Company has incurred a loss from operations of approximately $4,128,000 and a net loss of approximately $4,161,000 for the nine-month period ended September 27, 2014.  As of September 27, 2014, cash totaled approximately $1,204,000.  Subsequent to the nine-month period ended September 27, 2014, the Company entered into a loan and security agreement with Hercules Technology II, L.P., as lender (“Lender”) and Hercules Technology Growth Capital Inc., as agent.  Lender will provide the Company with access to a term loan up to $5 million.  The first $2.5 million of the term loan was funded at closing, and is repayable in installments over 30 months, following an initial interest-only period of twelve months after closing.  The remaining $2.5 million of the term loan can be drawn down at the Company’s option at any time but no later than July 31, 2015.  For more details on the term loan, please see Note 11. Subsequent Events of the Financial Statements.
 
With the term loan described above, management believes it will be able to support operations of the Company with its current cash and cash from operations through at least November 6, 2015; however there can be no assurance that unforeseen circumstances will not require the Company to seek additional financing.  If the Company determines that it shall require additional financing to further enable it to achieve its long-term strategic objectives, there can be no assurance that such financing will be available on terms favorable to it or at all.  If adequate financing is not available, the Company may delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative expenses.  The inability to raise additional financing may have a material adverse effect on the future performance of the Company.
 
Note 3.   Significant Accounting Policies
 
Basis of presentation :  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end.  Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date.  The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks, and will end on January 3, 2015.

 
Changes in accounting estimate : During the nine-month period ended September 27, 2014, the Company evaluated assumptions for estimating the fair value of the Company’s stock options.  The Company uses the Black-Scholes based option valuation model, which requires assumptions on (i) volatility, (ii) expected dividends, (iii) expected term and (iv) risk-free rate.  While evaluating the assumptions on volatility, the Company determined that the historical volatility the Company’s common stock needs to be considered when estimating the expected volatility.  Previously, the Company calculated expected volatility based on publicly held companies in similar industries and did not consider the historical volatility of the Company’s common stock, as the historical measurement period that was available to compute the volatility rate of the Company’s common stock was shorter than the expected life of the options.
 
For the stock options granted during the nine-month period ended September 27, 2014, the Company calculated expected volatility rate based on the combined volatility of publicly held companies in similar industries and volatility of the Company’s common stock.  A 20~30% weight was assigned to the volatility of the Company’s common stock as the historical volatility of the Company’s common stock covers only the period since June 2008 in a thinly traded market.  The weighted average expected volatility for the stock options granted during the nine-month period ended September 27, 2014 following the update to our estimate is approximately 73%.  The weighted average expected volatility would have been approximately 30%, had we computed solely based on the volatility rates of similarly situated public companies. For the year ended December 28, 2013, the weighted average expected volatility the Company used to estimate the fair value of the Company’s stock options granted was approximately 33%.

Inventories :  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  The amounts of major classes of inventory as of September 27, 2014 and December 28, 2013 are as follows:

   
September 27, 2014
   
December 28, 2013
 
Reference standards
  $ 1,715,507     $ 1,769,160  
Bulk ingredients
    866,509       694,965  
      2,582,016       2,464,125  
Less valuation allowance
    295,930       260,000  
    $ 2,286,086     $ 2,204,125  
 
Recent accounting standards : In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for us in our first quarter of fiscal 2018 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements.

 
In August 2014, the FASB issued ASU 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.”  Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this ASU provide that guidance.  In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures.  The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued).  The amendments in this ASU are effective for public and nonpublic entities for annual periods ending after December 15, 2016. Early adoption is permitted. On September 27, 2014, the Company early adopted ASU 2014-15.  The adoption of ASU 2014-15 had no impacts on the Company’s consolidated financial statements.
 
Note 4.   Loss Per Share Applicable to Common Stockholders
 
The following table sets forth the computations of loss per share amounts applicable to common stockholders for the three and nine months ended September 27, 2014 and September 28, 2013:
 
   
Three Months Ended
   
Nine Months Ended
 
   
September 27, 2014
   
September 28, 2013
   
September 27, 2014
   
September 28, 2013
 
                         
Net loss
  $ (659,653 )   $ (1,250,263 )   $ (4,160,811 )   $ (3,695,201 )
                                 
Basic and diluted loss per common share
  $ (0.01 )   $ (0.01 )   $ (0.04 )   $ (0.04 )
                                 
Weighted average common shares outstanding (1) :
    106,610,400       101,309,939       106,290,782       98,590,008  
                                 
Potentially dilutive securities (2) :
                               
  Stock options
    13,890,766       13,609,700       13,890,766       13,609,700  
  Warrants
    -       535,000       -       535,000  
 
(1) Includes 1,676,175 and 500,000 weighted average nonvested shares of restricted stock for the three months ended September 27, 2014 and September 28, 2013, respectively, and 1,606,380 and 500,000 weighted average nonvested shares of restricted stock for the nine months ended September 27, 2014 and September 28, 2013, respectively, which are participating securities that feature voting and dividend rights.
 
(2) Excluded from the computation of loss per share as their impact is antidilutive.
     
 
Note 5.   Investment in Affiliate
 
During the year ended December 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci International Inc. (“NeutriSci”) and consummated the sale of BluScience consumer product line to NeutriSci.  The Company is using the cost recovery method to account the sale transaction, which was estimated at approximately $3,157,804.  The consideration received consisted of following: (a) a $1,000,000 cash payment; (b) a $2,500,000 senior convertible secured note (convertible into 625,000 shares Series I Preferred Stock); and (c) 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci, representing an aggregate of 19% of the NeutriSci shares at the date of the transaction.

 
The Company has previously applied the equity method of accounting due to a significant influence that it had obtained from the financial instruments noted above, and the carrying value, which includes the Senior Note, was reflected as long-term investment in affiliate in the Company’s consolidated balance sheet at the date of transaction.  The initial carrying value of this investment recognized at the date of transaction was $2,157,804, which is the Company’s unrecovered cost or the difference between the net assets transferred to NeutriSci and the initial monetary consideration received.  The 669,708 shares of Series I Preferred Shares and the senior convertible secured note were accounted for as one long-term investment in NeutriSci.  Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets transferred has been recovered.
 
Sale of Senior Secured Convertible Note
 
On December 30, 2013, the Company assigned the Senior Note to an unrelated third party for $1,250,000.  $2,275,000 remained outstanding on the Senior Note at the date of the assignment.  The Company also paid legal fees of $7,500 out of the proceeds of the purchase price.  The Company also agreed to transfer to the third party a number of shares of preferred stock of NeutriSci having a value of $500,000 upon the earlier of (a) December 31, 2014; or (b) the consummation by NeutriSci of any action resulting in the shares of its common stock being listed on an exchange.  There is no recourse provision to the Company associated with the assignment of the note.  In connection with the assignment of the note, the Company paid Palladium Capital Advisors, LLC (“Palladium”), a placement agent, a cash fee of $150,000 and agreed to transfer to Palladium a number of shares of preferred stock of NeutriSci having a value of $50,000 upon the consummation by NeutriSci of any action resulting in the shares of its common stock being listed on an exchange.  The net proceeds received from the assignment of the Senior Note have been charged against the carrying value of the long-term investment in affiliate.
 
Subsequent to the consummation of the sale of BluScience consumer product line, NeutriSci has issued additional 950 shares of Series I Preferred Shares pursuant to anti-dilution provision.  There was no accounting transaction for this additional shares received as the Company is using the cost recovery method to account the BluScience sale transaction.  As of September 27, 2014, the Company holds a total of 670,658 shares of Series I Preferred Shares.
 
As of September 27, 2014, the Company has not transferred preferred stock of NeutriSci to either the unrelated party or Palladium.  Based on the latest estimates of share price of Neutrisci upon listing, the Company would transfer approximately 110,000 shares of Series I Preferred Shares to the unrelated party and approximately 11,000 shares of Series I Preferred Shares, contingent upon NeutriSci’s common stock being listed on an exchange.  If NeutriSci’s common stock does not list on an exchange by December 31, 2014, then the Company would transfer approximately 250,000 shares of Series I Preferred Shares and approximately 25,000 shares of Series I Preferred Shares based on the terms of the assignment of the note.
 
Loss of Significant Influence
 
As a result of the assignment of the Senior Note described above, the Company no longer has a significant influence on NeutriSci as of December 30, 2013.  As a result, the Company has discontinued applying equity method of accounting and has applied cost method of accounting from December 30, 2013.  The adjusted carrying amount as of December 30, 2013 became the new cost figure for the investment and no retrospective adjustments to the financial statements have been made.
 
The Company had elected to record equity method adjustments in losses on the investment in NeutriSci, with a three-month lag, as the financial information of NeutriSci was not available in a timely manner.  The equity method adjustment for the previously unaccounted NeutriSci’s operations from October 1, 2013 to December 31, 2013 is recorded during the nine-month period ended September 27, 2014, and is incorporated into the adjusted carrying amount of the investment.

 
Sales, gross profit, net loss of NeutriSci for the three months ended December 31, 2013 and the changes in carrying value and the Company ownership percentage through December 30, 2013 are summarized as follows:
 
   
December 31,
2013
       
Sales
  $ 60,575        
Gross profit
    33,619        
Net loss
  $ (435,208 )      
               
Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
       
               
   
Carrying
Value
   
Ownership
Percentage
 
At December 28, 2013
  $ 1,887,844       4.9 %
                 
Company's share of NeutriSci's loss for the three-month period ended December 31, 2013;  previously not recognized due to a three-month lag
    (21,543 )     -  
                 
Proceeds from assignment of the Senior Note
    (1,092,500 )     -  
                 
At December 30, 2013
  $ 773,801       4.9 %
 
Valuation assessment of Investment
 
As of September 27, 2014, the Company has determined that there is no other-than-temporary impairment of the carrying amounts of its investment in NeutriSci.  The Company will continue to monitor NeutriSci’s performance and evaluate if there are any such events or indicators to consider.
 
Note 6.   Leasehold Improvements and Equipment
 
Leasehold improvements and equipment consisted of the following:
 
   
September 27, 2014
   
December 28, 2013
 
             
Laboratory equipment
  $ 3,028,644     $ 2,782,364  
Leasehold improvements
    495,240       491,125  
Computer equipment
    329,737       372,851  
Furniture and fixtures
    13,039       18,313  
Office equipment
    7,877       7,877  
Construction in progress
    159,277       40,126  
      4,033,814       3,712,656  
Less accumulated depreciation
    2,740,112       2,649,417  
    $ 1,293,702     $ 1,063,239  
 
 
Depreciation expense on leasehold improvements and equipment included in the consolidated statement of operations for the nine months ended September 27, 2014 and September 28, 2013 was approximately $162,000 and $188,000, respectively.
 
During the nine months ended September 27, 2014, the Company disposed of approximately $56,000 of fully depreciated equipment.
 
Note 7.   Share-Based Compensation
 
7A. Employee Share-Based Compensation
 
Stock Option Plans
 
The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes option pricing model.  The table below outlines the weighted average assumptions for options granted to employees during the nine months ended September 27, 2014.
 
Nine Months Ended September 27, 2014
     
Expected volatility
    73.55 %
Expected dividends
    0.00 %
Expected term
 
5.7 years
 
Risk-free rate
    1.86 %
 
The weighted average grant date fair value of options granted during the nine months ended September 27, 2014 was $0.91.
 
Service Period Based Stock Options
 
The majority of options granted by the Company feature service conditions.  Accordingly, these options vest ratably over specified   periods of approximately 3 to 5 years following the date of grant.
 
The following table summarizes our stock option activity during   the nine months ended September 27, 2014:
 
         
Weighted Average
       
               
Remaining
   
Aggregate
 
   
Number of
   
Exercise
   
Contractual
   
Intrinsic
 
   
Shares
   
Price
   
Term
   
Value
 
Outstanding at December 28, 2013
    12,113,655     $ 1.06       7.43        
                               
Options Granted
    2,033,987       1.37       10.00        
Options Classification from Employee  to Non-Employee
    (113,151 )     0.76                
Options Exercised
    (511,642 )     0.88                
        Options Expired
    (253,900 )     1.00                
        Options Forfeited
    (628,634 )     1.11                
Outstanding at September 27, 2014
    12,640,315     $ 1.12       7.22     $ 1,475,920  
                                 
Exercisable at September 27, 2014
    8,822,108     $ 1.13       6.53     $ 1,071,805  

 
The aggregate intrinsic values in the table   above are before income taxes, based on the Company’s closing stock price of $1.06 on the last day of business for the period ended September 27, 2014.
 
As of September 27, 2014, there was approximately $2,035,000 of total unrecognized compensation expense expected to be recognized over a weighted average period of 2.12 years.
 
Restricted Stock
 
Restricted stock awards granted by the Company to employees have vesting conditions that are unique to each award.
 
The following table summarizes activity of restricted stock awards granted to employees at September 27, 2014 and changes during the nine months then ended:
 
         
Weighted Average
 
         
Award-Date
 
   
Shares
   
Fair Value
 
Unvested shares at December 28, 2013
    500,000     $ 0.69  
                 
Granted
    1,090,000       1.41  
Vested
    -       -  
        Forfeited
    -       -  
Unvested shares at September 27, 2014
    1,590,000     $ 1.18  
                 
Expected to Vest as of September 27, 2014
    1,590,000     $ 1.18  
 
On January 2, 2014, the Company awarded an aggregate of 1,090,000 shares of restricted stock to the Company’s officers and members of the board of directors.  These shares shall vest upon the earlier to occur of the following: (i) the market price of the Company’s stock exceeds a certain price, or (ii) one of other certain triggering events, including the termination of the officers and members of the board of directors without cause for any reason.  The fair values of these restricted stock awards were based on the trading price of the Company’s common stock on the date of grant.  The expense related to the restricted stock award has been amortized over the period of six months through July 1, 2014, as the Company determined the requisite service period to be 6 months as that is when they are eligible to vest.
 
Employee Option and Restricted Stock Compensation
 
The Company recognized compensation expense of approximately $388,000 and $2,359,000 in general and administrative expenses in the statement of operations for the three and nine months ended September 27, 2014, respectively, and $244,000 and $817,000 for the three and nine months ended September 28, 2013, respectively.

 
7B. Non-Employee Share-Based Compensation
 
Stock Option Plans
 
The following table summarizes activity of stock options granted to non-employees at September 27, 2014 and changes during the nine months then ended:
 
         
Weighted Average
       
               
Remaining
   
Aggregate
 
   
Number of
   
Exercise
   
Contractual
   
Intrinsic
 
   
Shares
   
Price
   
Term
   
Value
 
Outstanding at December 28, 2013
    847,300     $ 1.44       5.74        
                               
Options Granted
    90,000       1.24       10.00        
Options Classification from Employee  to Non-Employee
    113,151       0.76                
Options Exercised
    -       -                
        Options Forfeited
    -       -                
Outstanding at September 27, 2014
    1,050,451     $ 1.35       5.73     $ 64,067  
                                 
Exercisable at September 27, 2014
    960,451     $ 1.36       5.34     $ 64,067  
                                 
The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $1.06 on the last day of business for the period ended September 27, 2014.
 
Stock Awards
 
On July 1, 2014, the Company awarded 65,000 shares of the Company’s common stock that were fully vested and non-forfeitable to a non-employee.  The fair value of the award, which amounted to $83,850 was based on the trading price of the Company’s stock on the date of grant.  The expense related to this stock award is being amortized over the period of approximately 7 months, as the services relating to this award are being provided over this period of time.  The expense the Company recognized for this award was approximately $35,000 for the nine months ended September 27, 2014.  During the nine months ended September 28, 2013, the Company awarded an aggregate of 600,000 shares of the Company’s common stock to non-employees and recognized approximately $238,000 for the expense.
 
As of September 27, 2014, there was approximately $49,000 of total unrecognized compensation expense related to the stock award to a non-employee.  That cost is expected to be recognized over a period of approximately 4 months as of September 27, 2014.
 
Restricted Stock
 
Restricted stock awards granted by the Company to non-employees generally feature time vesting service conditions, specified in the respective service agreements.  Restricted stock awards issued to non-employees are accounted for at current fair value through the vesting period.  The fair value of vested non-employee restricted shares awarded during the nine months ended September 27, 2014 was approximately $15,000, which represents the market value of the Company’s common stock on respective vesting dates charged to expense.

 
The following table summarizes activity of restricted stock awards issued to non-employees at September 27, 2014 and changes during the nine months then ended:
 
         
Weighted Average
 
   
Shares
   
Fair Value
 
Unvested shares at December 28, 2013
    -     $ -  
                 
Granted
    96,000       1.30  
Vested
    (12,000 )     1.28  
        Forfeited
    -       -  
Unvested shares expected to vest at September 27, 2014
    84,000     $ 1.06  
 
As of September 27, 2014, there was approximately $87,000 of total unrecognized compensation expense related to the restricted stock award  to a non-employee.  That cost is expected to be recognized over a period of 3.4 years as of September 27, 2014.
 
Non-Employee Option, Stock and Restricted Stock Compensation
 
The Company recognized share-based compensation expense of approximately $43,000 and $109,000 in general and administrative expenses in the statement of operations for the three and nine months ended September 27, 2014, respectively, and $87,000 and $243,000 for the three and nine months ended September 28, 2013, respectively.
 
Note 8.   Stock Issuance
 
On June 11, 2014, the Company issued 44,605 shares of common stock to a vendor to settle an outstanding payable balance of $52,188.
 
On June 18, 2014, the Company issued 82,000 shares of common stock to a vendor to settle an outstanding payable balance of $76,306 and payment of 6 months of $3,000 per month monthly retainer fees from July 2014 through December 2014.
 
Note 9.   Business Segments
 
Since the year ended December 28, 2013, the Company has generated significant revenue from its ingredients operations and has made operational changes, including changes in the organizational structure to support the ingredients operations.  As a result, on December 29, 2013, the Company began segregating its financial results for ingredients operations, and has following three reportable segments.
 
Core standards, and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, reference materials, and related contract services.
 
Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries including the nutritional supplement, food and beverage and animal health industries.
 
Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
 
 
The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination.  The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.
 
   
Core Standards
         
Scientific and
             
   
and Contract
   
 
   
Regulatory
             
Three months ended September 27, 2014
 
Services
segment
   
Ingredients
segment
   
Consulting segment
   
Other
   
Total
 
Net sales
  $ 1,814,622     $ 2,031,250     $ 293,838     $ -     $ 4,139,710  
Cost of sales
    1,239,356       1,200,790       176,618       -       2,616,764  
                                         
Gross profit
    575,266       830,460       117,220       -       1,522,946  
                                         
Operating expenses:
                                       
Sales and marketing
    259,951       243,068       15,643       -       518,662  
General and administrative
    -       -       -       1,651,718       1,651,718  
Operating expenses
    259,951       243,068       15,643       1,651,718       2,170,380  
                                         
Operating income (loss)
  $ 315,315     $ 587,392     $ 101,577     $ (1,651,718 )   $ (647,434 )
 
   
Core Standards
         
Scientific and
             
   
and Contract
   
 
   
Regulatory
             
Three months ended September 28, 2013  
Services
segment
   
Ingredients
segment
   
Consulting segment
   
Other
   
Total
 
Net sales
  $ 1,574,970     $ 780,489     $ 362,749     $ -     $ 2,718,207  
Cost of sales
    1,309,562       484,511       173,947       -       1,968,020  
                                         
Gross profit
    265,408       295,977       188,802       -       750,187  
                                         
Operating expenses:
                                       
Sales and marketing
    328,043       165,025       12,000       -       505,068  
General and administrative
    -       -       -       1,453,611       1,453,611  
Loss from investment in affiliate
    -       -       -       33,281       33,281  
Operating expenses
    328,043       165,025       12,000       1,486,892       1,991,960  
                                         
Operating income (loss)
  $ (62,635 )   $ 130,952     $ 176,802     $ (1,486,892 )   $ (1,241,773 )
 
   
Core Standards
                         
   
and Contract
   
 
   
Regulatory
             
Nine months ended September 27, 2014  
Services segment
   
Ingredients
segment
   
Consulting segment
   
Other
   
Total
 
Net sales
  $ 5,407,455     $ 4,889,431     $ 773,116     $ -     $ 11,070,002  
Cost of sales
    3,728,521       2,962,505       472,256       -       7,163,282  
                                         
Gross profit
    1,678,934       1,926,926       300,860       -       3,906,720  
                                         
Operating expenses:
                                       
Sales and marketing
    694,523       793,414       66,840       -       1,554,777  
General and administrative
    -       -       -       6,458,027       6,458,027  
Loss from investment in affiliate
    -       -       -       21,543       21,543  
Operating expenses
    694,523       793,414       66,840       6,479,570       8,034,347  
                                         
Operating income (loss)
  $ 984,411     $ 1,133,512     $ 234,020     $ (6,479,570 )   $ (4,127,627 )
 
 
-15-

 
 
   
Core Standards
         
Scientific and
             
   
and Contract
   
 
   
Regulatory
             
Nine months ended September 28, 2013
 
Services segment
   
Ingredients
segment
   
Consulting segment
   
Other
   
Total
 
Net sales
  $ 4,978,727     $ 2,032,616     $ 808,610     $ (60,285 )   $ 7,759,668  
Cost of sales
    3,661,772       1,260,697       452,479       955       5,375,903  
                                         
Gross profit (loss)
    1,316,955       771,919       356,131       (61,240 )     2,383,765  
                                         
Operating expenses:
                                       
Sales and marketing
    1,120,897       599,395       14,600       131,159       1,866,051  
General and administrative
    -       -       -       4,155,792       4,155,792  
Loss from investment in affiliate
    -       -       -       33,281       33,281  
Operating expenses
    1,120,897       599,395       14,600       4,320,232       6,055,124  
                                         
Operating income (loss)
  $ 196,058     $ 172,524     $ 341,531     $ (4,381,472 )   $ (3,671,359 )
 
   
Core Standards and
   
Scientific and
             
   
Contract Services
   
Ingredients
   
Regulatory
Consulting
             
At September 27, 2014  
segment
   
segment
   
segment
   
Other
   
Total
 
Total assets
  $ 3,394,033     $ 2,618,062     $ 277,007     $ 2,410,049     $ 8,699,151  
 
   
Core Standards and
   
Scientific and
             
   
Contract Services
   
Ingredients
   
Regulatory
Consulting
             
At December 28, 2013  
segment
   
segment
   
segment
   
Other
   
Total
 
Total assets
  $ 2,952,270     $ 1,083,856     $ 139,765     $ 4,811,001     $ 8,986,892  


Note 10.   Commitments and Contingencies
 
Capitalized Lease Obligations
 
During the nine months ended September 27, 2014, the Company entered into two financing transactions to purchase laboratory equipment.  Under the lease terms, the Company will make monthly future lease payments, including interest, of approximately $2,000 and $5,000, respectively, for 60 months, for a total payment of approximately $122,000 and $271,000, respectively.  The Company has recorded a capital lease of approximately $100,000 and $223,000, respectively.  The equipment will be utilized in our core standards and contract services segment.
 
Employment Agreement with Troy Rhonemus
 
On March 6, 2014, the Company entered into an Employment Agreement (the “Rhonemus Agreement”) with Mr. Troy Rhonemus pursuant to which Mr. Rhonemus was appointed to serve as the Chief Operating Officer of the Company.  The Rhonemus Agreement provides for a base salary of $180,000, and provides for an annual cash bonus (based on performance targets) of up to 30% of his base salary (30% of this salary being the “Maximum Annual Bonus”), and provides for option grants of 250,000 shares of Common Stock.  The option grants were awarded on February 21, 2014 at an exercise price of $1.75 per share, which vest 33% one year from the date of grant with the remainder vesting in 24 equal monthly installments thereafter.  Upon termination, Mr. Rhonemus will be entitled to any accrued but unpaid base salary and any accrued but unpaid welfare and retirement benefits up to the termination date.  In addition, if Mr. Rhonemus leaves the Company for “Good Reason” (as defined in the Rhonemus Agreement), he will also be entitled to severance equal to two weeks of base salary for each full year of service to a maximum of eight weeks of the base salary.   In the event the Company terminates Mr. Rhonemus’ employment “without Cause,” Mr. Rhonemus will be entitled to severance equal to two weeks of base salary for each full year of service to a maximum of eight weeks of the base salary, or, if Mr. Rhonemus enters into a standard separation agreement, Mr. Rhonemus will receive continuation of base salary and health benefits, together with applicable fringe benefits as provided until the expiration of the term or renewal term then in effect, however, that in the case of medical and dental insurance, until the expiration of 12 months from the date of termination.
 
Legal Proceedings
 
The Company from time to time is involved in legal proceedings in the ordinary course of our business, which can include employment claims, product claims and patent infringements.  We do not believe that any of these claims and proceedings against us as they arise are likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.
 
During the nine-month period ended September 27, 2014, the Company settled and paid approximately $125,000 to a certain claimant.  This payment was recognized in general and administrative expenses in the statements of operations for the nine-month period ended September 27, 2014.
 
Note 11.   Subsequent Events
 
Subsequent to the nine-month period ended September 27, 2014, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Technology II, L.P., as lender (“Lender”) and Hercules Technology Growth Capital, Inc., as agent. Lender will provide us with access to a term loan of up to $5 million. The first $2.5 million of the term loan was funded at closing, and is repayable in equal monthly installments of principal and interest (mortgage style) over 30 months, following an initial interest-only period of twelve months after closing.  The remaining $2.5 million of the term loan can be drawn down at our option at any time but no later than July 31, 2015. In connection with the loan, the Company paid a $50,000 facility charge to Lender.

 
The term loan bears interest at the rate per year equal to the greater of either (i) 9.35% plus the prime rate as reported in The Wall Street Journal minus 3.25%, and (ii) 9.35%. The Company may prepay all, but no less than all, of the outstanding loan balance, subject to prepayment charges of 3% during the first twelve months following closing, 2% during the next twelve months and 1% thereafter. On the earliest to occur of the (a) the loan maturity date, (b) the date the Company prepays the outstanding loan balance or (c) the date the outstanding loan balance becomes due and payable, the Company will pay Lender an end of term charge equal to 3.75% of all amounts drawn under the loan.
 
The Loan Agreement further provides that, subject to certain conditions, any regularly scheduled installment of principal due to Lender may be paid, in whole or in part at the option of the Company or Lender, by converting a portion of the principal of the term loan into shares of the Company’s common stock (the “Conversion Shares”) at a conversion price of $1.293, in lieu of payment in cash.  The aggregate principal amount to be paid in Conversion Shares shall not exceed $1,000,000.  Of this amount 50% shall convert at the Lender’s option and 50% shall convert at the Company’s option.
 
Pursuant to the Loan Agreement, the Company issued Lender a warrant (the “Warrant”) to purchase 419,020 shares of our common stock at an exercise price of $1.062 per share, subject to customary adjustments under certain circumstances.   The Warrant is exercisable beginning on the date of issuance and expires five years from that date.
 
In connection with the Loan Agreement, the Company granted first priority liens and security interest in substantially all of our assets, exclusive of intellectual property and 35% of the capital stock of any foreign subsidiary, as collateral for the obligations under the Loan Agreement.  The Loan Agreement also contains representations and warranties by the Company and Lender, indemnification provisions in favor of Lender and customary covenants, and events of default.  Upon the occurrence of an event of default, a default interest rate of an additional 4% will be applied to the outstanding loan balances, and Lender may terminate its lending commitment, declare all outstanding obligations immediately due and payable, and take such other actions as set forth in the Loan Agreement.

 
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
GENERAL
 
This Quarterly Report on Form 10−Q (the “Form 10−Q”) contains “forward-looking statements,” as defined in Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s current expectations of the future results of its operations, performance and achievements. Forward-looking statements are covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company has tried, wherever possible, to identify these statements by using words such as “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends” and similar expressions. These statements reflect management’s current beliefs and are based on information now available to it. Accordingly, these statements are subject to certain risks, uncertainties and contingencies that could cause the Company’s actual results, performance or achievements in 2014 and beyond to differ materially from those expressed in, or implied by, such statements. Such statements, include, but are not limited to, statements contained in this Form 10-Q relating to our business, financial performance, business strategy, recently announced transactions and capital outlook.   Important factors that could cause actual results to differ materially from those in the forward- looking statements include: a continued decline in general economic conditions nationally and internationally; decreased demand for our products and services; market acceptance of our products; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; the inability to raise capital to fund continuing operations; changes in government regulation; the ability to complete customer transactions, and other factors  relating to our industry, our operations and results of operations and any businesses that may be acquired by us. Should one or more of these or other risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Additional risks, uncertainties, and other factors are set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ending December 28, 2013 and filed with the Commission on March 27, 2014 and in future reports the Company files with the Commission. Readers of this Form 10−Q should not place undue reliance on any forward-looking statements. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.

You should read the following discussion and analysis of the financial condition and results of operations of the Company together with the financial statements and the related notes presented in Item 1 of this Form 10-Q.
 
Overview
 
We discover, acquire, develop and commercialize proprietary-based ingredient technologies through our business model which utilizes our wholly-owned synergistic business units. These units include the supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, and reference materials, related contract services, and proprietary ingredients.  We perform chemistry-based analytical services at our laboratory in Boulder, Colorado, typically in support of quality control or quality assurance activities within the dietary supplement industry. Through our subsidiary Spherix Consulting, Inc., we also provide scientific and regulatory consulting to clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
 
The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles.  The preparation of these financial statements requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues, if any, and expenses during the reporting periods.  On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below.  We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions.

 
Subsequent to the nine-month period ended September 27, 2014, the Company entered into a loan and security agreement with Hercules Technology II, L.P. (“Lender”).  Lender will provide the Company with access to a term loan up to $5 million.  The first $2.5 million of the term loan was funded at closing, and is repayable in installments over 30 months, following an initial interest-only period of twelve months after closing.  The remaining $2.5 million of the term loan can be drawn down at the Company’s option at any time but no later than July 31, 2015.

With the term loan described above, we anticipate that our current cash and cash generated from operations will be sufficient to meet our projected operating plans through at least November 6, 2015. We may, however, seek additional capital prior to November 6, 2015, both to meet our projected operating plans after November 6, 2015 and/or to fund our longer term strategic objectives.

Additional capital may come from public and/or private stock or debt offerings, borrowings under lines of credit or other sources. These additional funds may not be available on favorable terms, or at all.  Further, if we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution and the new equity or debt securities we issue may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our products or proprietary technologies, or to grant licenses on terms that are not favorable to us. If we cannot raise funds on acceptable terms, we may not be able to develop or enhance our products, obtain the required regulatory clearances or approvals, achieve long term strategic objectives, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer requirements. Any of these events could adversely affect our ability to achieve our development and commercialization goals, which could have a material and adverse effect on our business, results of operations and financial condition. If we are unable to establish small to medium scale production capabilities through our own plant or though collaboration we may be unable to fulfill our customers’ requirements. This may cause a loss of future revenue streams as well as require us to look for third party vendors to provide these services. These vendors may not be available, or charge fees that prevent us from pricing competitively within our markets.

Some of our operations are subject to regulation by various state and federal agencies.  In addition, we expect a significant increase in the regulation of our target markets. Dietary supplements are subject to FDA, FTC and U.S. Department of Agriculture regulations relating to composition, labeling and advertising claims. These regulations may in some cases, particularly with respect to those applicable to new ingredients, require a notification that must be submitted to the FDA along with evidence of safety. There are similar regulations related to food additives.

Results of Operations
 
We generated net sales of $11,070,002 for the nine-month period ended September 27, 2014 as compared to $7,759,668 for the nine-month period ended September 28, 2013. We incurred a net loss of $4,160,811 for the nine-month period ended September 27, 2014 as compared with a net loss of $3,695,201 incurred for the nine-month period ended September 28, 2013. This equated to a $0.04 basic and diluted loss per share for the nine-month period ended September 27, 2014 as compared with a $0.04 basic and diluted loss per share for the nine-month period ended September 28, 2013.
 
Over the next two years, we plan to continue to increase research and development efforts for our line of proprietary ingredients, subject to available financial resources.
 
Net Sales
 
Net sales consist of gross sales less discounts and returns .   Net sales increased by 52% to $4,139,710 for the three-month period ended September 27, 2014 as compared to $2,718,207 for the three-month period ended September 28, 2013.  The core standards and contract services segment generated net sales of $1,814,622 for the three-month period ended September 27, 2014.  This is an increase of 15%, compared to $1,574,970 for three-month period ended September 28, 2013.  This increase was primarily due to increased sales of analytical testing and contract services.  The ingredients segment generated net sales of $2,031,250 for the three-month period ended September 27, 2014.  This is an increase of 160%, compared to $780,489 for the three-month period ended September 28, 2013.  This increase was due to the increased sales throughout most of the ingredients we sell, including “NIAGEN,” “PTEROPURE,” and “PURENERGY.” The scientific and regulatory consulting segment generated net sales of $293,838 for the three-month period ended September 27, 2014.  This is a decrease of 19%, compared to $362,749 for the three-month period ended September 28, 2013.  There were fewer consulting projects completed during the three-month period ended September 27, 2014, resulting from client related delays.

 
For the nine-month period ended September 27, 2014, net sales increased by 43% to $11,070,002 as compared to $7,759,668 for the nine-month period ended September 28, 2013.  The core standards and contract services segment generated net sales of $5,407,455 for the nine-month period ended September 27, 2014.  This is an increase of 9%, compared to $4,978,727 for the nine-month period ended September 28, 2013.  This increase was due to increased sales of both phytochemical references standards and contract services.  The ingredients segment generated net sales of $4,889,431 for the nine-month period ended September 27, 2014.  This is an increase of 141%, compared to $2,032,616 for the nine-month period ended September 28, 2013.  This increase was due to the increased sales throughout most of the ingredients we sell, including “NIAGEN,” “PTEROPURE,” and “PURENERGY.”  The scientific and regulatory consulting segment generated net sales of $773,116 for the nine-month period ended September 27, 2014.  This is a decrease of 4%, compared to $808,610 for the nine-month period ended September 28, 2013.  There were fewer consulting projects completed during the nine-month period ended September 27, 2014 than during the comparable period in 2013.
 
Cost of Sales
 
Cost of sales include raw materials, labor, overhead, and delivery costs. Cost of sales for the three-month period ended September 27, 2014 was $2,616,764 as compared with $1,968,020 for the three-month period ended September 28, 2013.  As a percentage of net sales, this represented a 9% decrease for the three-month period ended September 27, 2014 compared to the three-month period ended September 28, 2013.  The cost of sales as a percentage of net sales for the core standards and contract services segment for the three-month period ended September 27, 2014 was 68% compared to 83% for the three-month period ended September 28, 2013.  This percentage decrease in cost of sales is largely due to increased sales in analytical testing and contract services area, which the sales increased about 34% compared to the comparable period in 2013.  Fixed labor costs make up the majority of costs for analytical testing and contract services and these fixed labor costs did not decrease in proportion to sales.  The cost of sales as a percentage of net sales for the ingredients segment for the three-month period ended September 27, 2014 was 59% compared to 62% for the three-month period ended September 28, 2013.  This percentage decrease in cost of sales is largely due to the increased purchasing volume, which we were able to obtain better purchasing costs from our suppliers as a result.  The cost of sales as a percentage of net sales for the scientific and regulatory consulting segment for the three-month period ended September 27, 2014 was 60% compared to 48% for the three-month period ended September 28, 2013.  The percentage increase in cost of sales is largely due to decreased sales as fixed labor costs make up the majority of costs for the consulting segment.
 
Cost of sales for the nine-month period ended September 27, 2014 was $7,163,282 versus $5,375,903 for the nine-month period ended September 28, 2013.  As a percentage of net sales, this represented 5% decrease for the nine-month period ended September 27, 2014 compared to the nine-month period ended September 28, 2013.  The cost of sales as a percentage of net sales decreased overall as our revenue mix changed with increased revenue from ingredients segment.  The cost of sales as a percentage of net sales for the core standards and contract services segment for the nine-month period ended September 27, 2014 was 69% compared to 74% for the nine-month period ended September 28, 2013.  The percentage decrease in cost of sales is mainly due to increased sales in analytical testing and contract services area, as fixed labor and equipment costs consist of the majority of costs for analytical testing and contract services area.  The cost of sales as a percentage of net sales for the ingredients segment for the nine-month period ended September 27, 2014 was 61%.  This percentage was 62% for the comparable period in 2013.  The cost of sales as a percentage of net sales for the scientific and regulatory consulting segment for the nine-month period ended September 27, 2014 was 61%, compared to 56% for the nine-month period ended September 28, 2013.  The increase in cost of sales was largely due to completing fewer consulting projects during the nine-month period ended September 27, 2014 than during the comparable period in 2013.
 
Gross Profit
 
Gross profit is net sales less the cost of sales and is affected by a number of factors including product mix, competitive pricing and costs of products and services. Our gross profit increased to $1,522,946 for the three-month period ended September 27, 2014 from $750,187, for the three-month period ended September 28, 2013.  For the core standards and contract services segment, our gross profit increased 117% to $575,266 for the three-month period ended September 27, 2014 from $265,408 for the three-month period ended September 28, 2013.  The increased sale of analytical testing and contract services which resulted in a higher labor utilization rate as well as increased fixed cost coverage was the main reason for the increase in gross profit.  For the ingredients segment, our gross profit increased to $830,460 for the three-month period ended September 27, 2014 from $295,977 for the three-month period ended September 28, 2013.  The increased sales throughout the ingredient portfolio we offer was the main reason for the increase in gross profit.  For the scientific and regulatory consulting segment, our gross profit decreased 38% to $117,220 for the three-month period ended September 27, 2014 from $188,802 for the three-month period ended September 28, 2013.  The decrease in sales which resulted in a lower labor utilization rate was the reason for the decrease in gross profit.

 
Our gross profit increased to $3,906,720 for the nine-month period ended September 27, 2014 from $2,383,765 for the nine-month period ended September 28, 2013.  For the core standards and contract services segment, our gross profit increased 27% to $1,678,934 for the nine-month period ended September 27, 2014 from $1,316,955 for the nine-month period ended September 28, 2013.  The increased sales was the primary reason for the increase in gross profit.  For the ingredients segment, our gross profit increased to $1,926,926 for the nine-month period ended September 27, 2014 from $771,919 for the nine-month period ended September 28, 2013.  The increased sales throughout the ingredient portfolio we offer was the main reason for the increase in gross profit.  For the scientific and regulatory consulting segment, our gross profit decreased 16% to $300,860 for the nine-month period ended September 27, 2014 from $356,131 for the nine-month period ended September 28, 2013.  The decrease in sales which resulted in a lower labor utilization rate was the reason for the decrease in gross profit.
 
Operating Expenses-Sales and Marketing
 
Sales and Marketing Expenses consist of salaries, advertising and marketing expenses. Sales and marketing expenses for the three-month period ended September 27, 2014 were $518,662 as compared to $505,068 for the three-month period ended September 28, 2013.  For the core standards and contract services segment, sales and marketing expenses for the three-month period ended September 27, 2014 decreased to $259,951 as compared to $328,043 for the three-month period ended September 28, 2013.  This decrease was largely due to operational changes in sales and marketing staff and a decrease in marketing and advertising spend.  For the ingredients segment, sales and marketing expenses for the three-month period ended September 27, 2014 increased to $243,068 as compared to $165,025 for the three-month period ended September 28, 2013.  The increase was largely due to increased marketing efforts for our line of proprietary ingredients.  For the scientific and regulatory consulting segment, sales and marketing expenses for the three-month period ended September 27, 2014 increased to $15,643, compared to $12,000 for the three-month period ended September 28, 2013.
 
Sales and marketing expenses for the nine-month period ended September 27, 2014 were $1,554,777 as compared to $1,866,051 for the nine-month period ended September 28, 2013.  For the core standards and contract services segment, sales and marketing expenses for the nine-month period ended September 27, 2014 decreased to $694,523 as compared to $1,120,897 for the nine-month period ended September 28, 2013.  This decrease was largely due to operational changes in sales and marketing staff and a decrease in marketing and advertising spend.  For the ingredients segment, sales and marketing expenses for the nine-month period ended September 27, 2014 increased to $793,414 as compared to $599,395 for the nine-month period ended September 28, 2013.  The increase was largely due to increased marketing efforts for our line of proprietary ingredients.  For the scientific and regulatory consulting segment, sales and marketing expenses for the nine-month period ended September 27, 2014 were $66,840, compared to $14,600 for the nine-month period ended September 28, 2013.  This increase was largely due to our increased marketing efforts to raise the awareness of our consulting services within the industry.  Lastly, we incurred $131,159 in sales and marketing expenses for our BluScience product line during the nine-month period ended September 28, 2013.  We did not have such expenses for the comparable period in 2014 as we sold the BluScience product line on March 28, 2013.
 
Operating Expenses-General and Administrative
 
General and Administrative Expenses consist of research and development, general company administration, IT, accounting and executive management. General and administrative expenses for the three-and nine-month periods ended September 27, 2014 were $1,651,718 and $6,458,027 compared to $1,453,611 and $4,155,792 for the three- and nine-month periods ended September 28, 2013.  One of the factors that contributed to this increase is an increase in share-based compensation.  For the three- and nine-month periods ended September 27, 2014, our share-based compensation increased to $431,452 and $2,467,720, respectively, compared to $331,304 and $1,059,653 for the comparable periods in 2013.  During the nine-month period ended September 27, 2014, the Company recognized expenses for the 1,090,000 shares of restricted stock granted to the Company’s officers and members of the board of directors, which resulted in the increase in share-based compensation expense.  Another factor that contributed to the increase in general and administrative expenses is an increase in research and development expenses for our line of proprietary ingredients.  Our research and development expenses increased to $152,687 and $360,340 for the three- and nine-month periods ended September 27, 2014, as compared to $83,783 and $120,638 for the three- and nine-month periods ended September 28, 2013.  In addition, during the nine-month period ended September 27, 2014, there was an increase in wages as a result of hiring additional personnel to support our operations, including an in-house legal counsel.  Lastly, there was one-time expense of $125,000 during the nine-month period ended September 27, 2014, which we have paid as a settlement fee to a certain claimant.

 
Non-operating income- Interest Income
 
Interest income consists of interest earned on money market accounts . Interest income for the three- and nine-month periods ended September 27, 2014 was $230 and $1,175 as compared to $179 and $679 for the three- and nine-month periods ended September 28, 2013.
 
Non-operating Expenses- Interest Expense
 
Interest expense consists of interest on capital leases. Interest expense for the three- and nine-month periods ended September 27, 2014 was $12,449 and $34,359 as compared to $8,669 and $24,521 for the three- and nine-month periods ended September 28, 2013.  The increase of the interest expense is largely due to a new capital lease of approximately $223,000 we entered on March 30, 2014.
 
Depreciation and Amortization
 
Depreciation expense for the nine-month period ended September 27, 2014, was approximately $161,712 as compared to $187,667 for the nine-month period ended September 28, 2013. We depreciate our assets on a straight-line basis, based on the estimated useful lives of the respective assets.  Amortization expense of intangible assets for the nine-month period ended September 27, 2014, was approximately $24,826 as compared to $16,819 for the nine-month period ended September 28, 2013.  We amortize intangible assets using a straight-line method over 10 years.
 
Liquidity and Capital Resources
 
From inception and through September 27, 2014, we have incurred aggregate losses of approximately $38 million. These losses are primarily due to expenses associated with the development and expansion of our operations. These operations have been financed through capital contributions and the issuance of common stock and warrants through private placements and through our registered direct offering.
 
Our board of directors periodically reviews our capital requirements in light of our proposed business plan. Our future capital requirements will remain dependent upon a variety of factors, including cash flow from operations, the ability to increase sales, increasing our gross profits from current levels, reducing selling and administrative expenses as a percentage of net sales, continued development of customer relationships, and our ability to market our new products successfully. However, based on our results from operations, we may determine that we need additional financing to implement our business plan.  There can be no assurance that any such financing will be available on terms favorable to us or at all. Without adequate financing we may have to further delay or terminate product and service expansion and curtail certain selling, general and administrative expenses. Any inability to raise additional financing would have a material adverse effect on us.

Subsequent to the nine-month period ended September 27, 2014, the Company entered into a loan and security agreement with Hercules Technology II, L.P. (“Lender”).  Lender will provide the Company with access to a term loan up to $5 million.  The first $2.5 million of the term loan was funded at closing, and is repayable in installments over 30 months, following an initial interest-only period of twelve months after closing.  The remaining $2.5 million of the term loan can be drawn down at the Company’s option at any time but no later than July 31, 2015.  For more details on the term loan, please see Note 11. Subsequent Events presented in Item 1 of this Form 10-Q.

With the term loan described above, we anticipate that our current levels of capital will be sufficient to meet our projected operating plans through at least November 6, 2015.  We may however seek additional capital prior to November 6, 2015, both to meet our projected operating plans through and after November 6, 2015 and to fund our longer term strategic objectives. To the extent we are unable to raise additional cash or generate sufficient revenue to meet our projected operating plans prior to November 6, 2015, we will revise our projected operating plans accordingly.

 
Net cash used in operating activities

Net cash used in operating activities for the nine months ended September 27, 2014 was approximately $2,335,000 as compared to approximately $2,173,000 for the nine months ended September 28, 2013.  Along with the net loss, we experienced an increase in trade receivables commensurate with the increase in net sales and fulfilled performance obligations relative to customer deposits, which together comprise of our largest uses of cash during the nine months ended September 27, 2014.  Net cash used in operating activities for the nine months ended September 28, 2013 largely reflects a decrease in accounts payable and an increase in inventories along with the net loss.

We expect our operating cash flows to fluctuate significantly in future periods as a result of fluctuations in our operating results, shipment timetables, accounts receivable collections, inventory management, and the timing of our payments, among other factors.

Net cash provided by investing activities

Net cash provided by investing activities was approximately $950,000 for the nine months ended September 27, 2014, compared to approximately $1,038,000 for the nine months ended September 28, 2013.  Net cash provided by investing activities for the nine months ended September 27, 2014 principally consisted of proceeds received from the assignment of the Senior Note issued by NeutriSci to an unrelated third party.  NeutriSci originally issued the Senior Note to the Company as a part of the consideration for the purchase of the BluScience product line.  Net cash provided by investing activities for the nine months ended September 28, 2013 mainly consisted of cash consideration received from NeutriSci from the sale of BluScience product line as well as a repayment received from the Senior Note issued by NeutriSci.

Net cash provided by financing activities

Net cash provided by financing activities was approximately $327,000 for the nine months ended September 27, 2014, compared to approximately $1,702,000 provided by for the nine months ended September 28, 2013.  Net cash provided by financing activities for the nine months ended September 27, 2014 mainly consisted of proceeds from exercise of stock options.  Net cash provided by financing activities for the nine months ended September 28, 2013 mainly consisted of proceeds from exercise of warrants.

Dividend policy
 
We have not declared or paid any dividends on our common stock. We presently intend to retain earnings for use in our operations and to finance our business. Any change in our dividend policy is within the discretion of our Board of Directors and will depend, among other things, on our earnings, debt service and capital requirements, restrictions in financing agreements, if any, business conditions, legal restrictions and other factors that our Board of Directors deems relevant.
 
Off-Balance Sheet Arrangements
 
During the nine months ended September 27, 2014, we had no off-balance sheet arrangements other than ordinary operating leases as disclosed in the “Financial Statements and Supplementary Data” section of the Company’s Annual Report on Form 10-K for the year ending December 28, 2013 and filed with the Commission on March 27, 2014.
 
Recent Licensing Agreement
 
On September 19, 2014, the Company entered into a First Amendment to the License Agreement (the “First Amendment”) with The Regents of the University of California Corporation (“UC”).  The First Amendment amends the Exclusive License Agreement (“the Agreement”) dated September 8, 2011, by and between the Company and UC which was filed as Exhibit 10.2 to the Company’s Form 10-Q filed with the Commission on November 10, 2011.

 
Under the terms of the First Amendment, UC granted to the Company a worldwide, exclusive, sublicensable right and license to use certain additional patent rights relating to the use of the compound known as Pterostilbene in a specified field of use.  Pterostilbene is a compound found in blueberries, grapes and other small fruits, as well as the bark of some trees.  The Agreement terminates on the earliest of (i) the expiration date or abandonment of the last valid claim of the patent rights licensed under the Agreement, (ii) failure by the Company to meet certain pre-development milestones or an uncured default by the Company under the Agreement or (iii) upon prior written notice given by the Company.

As consideration for the additional licenses granted, the Company will make additional cash payments to UC, including certain annual license maintenance fees, earned royalties on net sales of additional licensed products subject to a certain minimum amount, payments in the aggregate amount of $60,000 upon the completion of certain strategic milestones, as well as other consideration associated with sublicensing.  The license issuance fee of $10,000 has been capitalized as an intangible asset and is being amortized over 10 years using a straight-line method.  The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by reference to the redacted version of the First Amendment, which is filed as Exhibit 10.1 to this quarterly report.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
Not Applicable

ITEM 4.  CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures
 
Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a – 15(e) and 15d – 15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this quarterly report. They have concluded that, based on such evaluation, our disclosure controls and procedures were effective as of September 27, 2014.
 
Changes in Internal Control over Financial Reporting
 
There was no change in internal control over financial reporting (as defined in Rule 13a−15(f) promulgated under the Securities Exchange Act of 1934) that occurred during the Company’s third fiscal quarter that has materially affected or is reasonably likely to materially affect the Company’s internal control over financial reporting.


PART II - OTHER INFORMATION
 
ITEM 1.      LEGAL PROCEEDINGS
 
We are not involved in any legal proceedings which management believes may have a material adverse effect on our business, financial condition, operations, cash flows, or prospects.  The Company from time to time is involved in legal proceedings in the ordinary course of our business, which can include employment claims, product claim, patent infringement, etc. We do not believe that any of these claims and proceedings against us as they arise are likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.
 
ITEM 2.      UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
On July 1, 2014, we issued 65,000 shares of common stock to a vendor as a part of compensation for certain services to be provided through January 31, 2015.
 
ITEM 3.      DEFAULTS UPON SENIOR SECURITIES
 
None.

ITEM 4.      MINE SAFETY DISCLOSURES
 
Not applicable.

ITEM 5.      OTHER INFORMATION
 
None.

ITEM 6.      EXHIBITS
 
Exhibit No .   Description of Exhibits
10.1
 
First Amendment to the License Agreement, effective as of September 5, 2014 between the Regents of the University of California and ChromaDex, Inc. (1)
31.1
 
Certification of the Chief Executive Officer pursuant to §240.13a−14 or §240.15d−14 of the Securities Exchange Act of 1934, as amended
31.2
 
Certification of the Chief Financial Officer pursuant to §240.13a−14 or §240.15d−14 of the Securities Exchange Act of 1934, as amended
32.1
 
Certification pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)

(1)
A redacted version of this Exhibit is filed herewith.  An un-redacted version of this Exhibit has been separately filed with the Commission pursuant to an application for confidential treatment.  The confidential portions of the Exhibit have been omitted and are marked by an asterisk.

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 

ChromaDex Corporation
                          (Registrant)


Date:  November 6, 2014                                                                                                  /s/ THOMAS C. VARVARO
Thomas C. Varvaro
Duly Authorized Officer and Chief Financial Officer
Exhibit 10.1
 
[*] INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION
 
FIRST AMENDMENT TO THE LICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND CHROMADEX INC.
 
This first amendment (the “ First Amendment ”), dated Sept 5th, 2014 (the “ Effective Date ”), is made by and between The Regents of the University of California (“ The Regents ”), a California corporation having its statewide administrative offices at 1111 Franklin Street, 12 th Floor, Oakland, California 94607-5200, acting through the offices of The University of California, Irvine located at 5171 California Ave, Suite 150 CA 92697-7700 and ChromaDex Inc . (“ Licensee ”) having a principal place of business at 10005 Muirlands Blvd, Suite G, Irvine, CA 92618 and amends the license